DUB-IN-2
Based on 21 publication(s) in Google Scholar
DUB-IN-2 is a potent deubiquitinase inhibitor with an IC50 of 0.28 μM for USP8.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.92%
- CAS. Nr.: 924296-19-5
- Formel: C15H9N5O
- Molecular Weight:275.26
-
Speicherung:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biologische Aktivität
-
Chemical Information
-
Lösungsmittel & Löslichkeit
- Reinheit & Dokumentation
- Verweise
-
Help & FAQs
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
-
Ubiquitination Compound Library
HY-L050
-
Metabolic Enzyme Compound Library
HY-L146
-
Protease Inhibitor Library
HY-L147
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
High-Throughput Bioactive Compound Library
HY-L205
-
Posttranslational Modification Library
HY-L226
Publications Citing Use of MedChemExpress (MCE) DUB-IN-2
More- Nat Commun. 2025 May 16;16(1):4564. [Abstract]
- Nat Commun. 2022 Mar 31;13(1):1700. [Abstract]
- Cell Death Differ. 2023 Feb;30(2):560-575. [Abstract]
- Cell Death Differ. 2020 Apr;27(4):1341-1354. [Abstract]
- Cell Death Dis. 2026 Jan 21;17(1):98. [Abstract]
- Cell Death Dis. 2022 Mar 31;13(3):286. [Abstract]
- J Immunother Cancer. 2026 Jan 14;14(1):e013498. [Abstract]
- NPJ Precis Oncol. 2025 Mar 12;9(1):69. [Abstract]
- Cell Chem Biol. 2021 Jun 17;28(6):855-865.e9. [Abstract]
- Cell Rep. 2024 May 24;43(6):114248. [Abstract]
- J Med Chem. 2022 Oct 27;65(20):13645-13659. [Abstract]
- J Heart Lung Transplant. 2024 Jan;43(1):120-133. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2026 May 14:120159. [Abstract]
- FASEB J. 2021 Aug;35(8):e21800. [Abstract]
- Life Sci Alliance. 2019 Apr 15;2(2):e201900392. [Abstract]
- Theriogenology. 2025 Dec 24:254:117795. [Abstract]
- Endocr J. 2020 Feb 28;67(2):177-184. [Abstract]
- Drug Repurposing. 2026 Jan 30.
- bioRxiv. 2025 March 01.
- bioRxiv. 2024 Apr 26.
- L’UNIVERSITE GRENOBLE ALPES. 2021 Apr 13.
Customer Validation & Images
-
WB
Biologische Aktivität
IC50: 0.28 μM (USP8)[1]
DUBs-IN-2 (compound 22 e) is a potent USP8 inhibitor with an IC50 of 0.28 μM, and has no effect on USP7, with an IC50 of >100 μM. DUBs-IN-2 inhibits the viability of HCT116 colon cell line and PC-3 prostate cancer cell line with IC50 values of 0.5-1.5 μM[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS. Nr. 924296-19-5
-
Appearance Solid
-
Molecular Weight 275.26
-
Formel C15H9N5O
-
Color Light yellow to yellow
-
SMILES
N#CC1=C(C#N)N=C2C(/C(C3=C2C=CC=C3)=N/OCC)=N1
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month
Publications (21)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
2025 May 16;16(1):4564. PMID: 40379682 -
Nat Commun
USP8 inhibition reshapes an inflamed tumor microenvironment that potentiates the immunotherapy. [Abstract]2022 Mar 31;13(1):1700. PMID: 35361799 -
Cell Death Differ
Targeting ubiquitin-specific protease 8 sensitizes anti-programmed death-ligand 1 immunotherapy of pancreatic cancer. [Abstract]2023 Feb;30(2):560-575. PMID: 36539510 -
Cell Death Differ
Deubiquitylation and stabilization of Notch1 intracellular domain by ubiquitin-specific protease 8 enhance tumorigenesis in breast cancer. [Abstract]2020 Apr;27(4):1341-1354. PMID: 31527799 -
Cell Death Dis
Positive feedback regulation between USP8 and Hippo/YAP axis drives triple-negative breast cancer progression. [Abstract]2026 Jan 21;17(1):98. PMID: 41565619 -
Cell Death Dis
2022 Mar 31;13(3):286. PMID: 35361778 -
J Immunother Cancer
CD47 destabilization via manipulating the SPOP-USP2 axis augments macrophage phagocytosis and cancer immunotherapy. [Abstract]2026 Jan 14;14(1):e013498. PMID: 41534899 -
NPJ Precis Oncol
Targeting USP8 causes synthetic lethality through degradation of FGFR2 in ARID1A-deficient ovarian clear cell carcinoma. [Abstract]2025 Mar 12;9(1):69. PMID: 40074856 -
Cell Chem Biol
Development of potent and selective inhibitors targeting the papain-like protease of SARS-CoV-2. [Abstract]2021 Jun 17;28(6):855-865.e9. PMID: 33979649 -
Cell Rep
Stress granule-localized USP8 potentiates cGAS-mediated type I interferonopathies through deubiquitination of DDX3X. [Abstract]2024 May 24;43(6):114248. PMID: 38795350 -
J Med Chem
Discovery of Potent OTUB1/USP8 Dual Inhibitors Targeting Proteostasis in Non-Small-Cell Lung Cancer. [Abstract]2022 Oct 27;65(20):13645-13659. PMID: 36221183 -
J Heart Lung Transplant
Central role of ubiquitin-specific protease 8 in leptin signaling pathway in pulmonary arterial hypertension. [Abstract]2024 Jan;43(1):120-133. PMID: 37704159 -
Biochim Biophys Acta Mol Cell Res
2026 May 14:120159. PMID: 42140526 -
FASEB J
2021 Aug;35(8):e21800. PMID: 34324733 -
Life Sci Alliance
Inhibition of the deubiquitinase USP8 corrects a Drosophila PINK1 model of mitochondria dysfunction. [Abstract]2019 Apr 15;2(2):e201900392. PMID: 30988163 -
Theriogenology
Regulation of autophagy-Ferroptosis crosstalk by the SLC7A11-GPX4 axis during sperm capacitation. [Abstract]2025 Dec 24:254:117795. PMID: 41483535 -
Endocr J
Ubiquitin-specific protease 8 inhibitor suppresses adrenocorticotropic hormone production and corticotroph tumor cell proliferation. [Abstract]2020 Feb 28;67(2):177-184. PMID: 31666445
DUB-IN-2 purchased from MedChemExpress. Usage Cited in: Endocr J. 2020 Feb 28;67(2):177-184. [Abstract]
Effects of DUBs-IN-2 on EGFR protein expression in AtT-20 corticotroph tumor cells.Time-dependent effects of DUBs-IN-2 on EGFR protein expression. AtT-20 cells are incubated for 2, 6, and 24 h with 10 μM DUBs-IN-2, and western blot analysis was performed to examine EGFR protein levels. Dose-dependent effects of DUBs-IN-2 on EGFR protein expression. AtT-20 cells are incubated for 24 h with 0.1-10 μM of DUBs-IN-2.
-
-
-
-
Lösungsmittel & Löslichkeit
DMSO : 16.67 mg/mL (60.56 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: 1 mg/mL (3.63 mM); Suspended solution; Need ultrasonic
This protocol yields a suspended solution of 1 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (10.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 50% PEG300 50% Saline
Solubility: 1.5 mg/mL (5.45 mM); Suspended solution; Need ultrasonic
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (278 KB)
-
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
-
Handling Instructions (2659 KB)
Verweise
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.6329 mL | 18.1646 mL | 36.3293 mL | 90.8232 mL |
| 5 mM | 0.7266 mL | 3.6329 mL | 7.2659 mL | 18.1646 mL | |
| 10 mM | 0.3633 mL | 1.8165 mL | 3.6329 mL | 9.0823 mL | |
| 15 mM | 0.2422 mL | 1.2110 mL | 2.4220 mL | 6.0549 mL | |
| 20 mM | 0.1816 mL | 0.9082 mL | 1.8165 mL | 4.5412 mL | |
| 25 mM | 0.1453 mL | 0.7266 mL | 1.4532 mL | 3.6329 mL | |
| 30 mM | 0.1211 mL | 0.6055 mL | 1.2110 mL | 3.0274 mL | |
| 40 mM | 0.0908 mL | 0.4541 mL | 0.9082 mL | 2.2706 mL | |
| 50 mM | 0.0727 mL | 0.3633 mL | 0.7266 mL | 1.8165 mL | |
| 60 mM | 0.0605 mL | 0.3027 mL | 0.6055 mL | 1.5137 mL |
DUB-IN-2 Related Classifications
HY-50737A Related Classifications
Powered by Bioz